Home/Pipeline/S6K1 Program

S6K1 Program

Oncology (unspecified)

PreclinicalActive (Licensed)

Key Facts

Indication

Oncology (unspecified)

Phase

Preclinical

Status

Active (Licensed)

Company

Sentinel Oncology

About Sentinel Oncology

Sentinel Oncology is a private, preclinical-stage biotech company leveraging its medicinal chemistry expertise to develop targeted small molecule inhibitors for cancers with high unmet need, especially those affecting the brain. Its pipeline features three late-stage preclinical programs, with its lead asset, SOL578 (a Chk1 inhibitor), having entered Phase 1 trials in 2023 via a licensing agreement with PharmaEngine. The company employs a collaborative business model, partnering with pharmaceutical and biotech organizations to advance and commercialize its programs.

View full company profile

Therapeutic Areas

Oncology Rare Neurological Disorders

Other Oncology (unspecified) Drugs

Drug	Company	Phase	Status
Oncology Vaccine Program	CHAIN Biotech	Pre-clinical	Active
ARX305	NovoCodex Biopharmaceuticals	Phase 1	Active
ARX788	NovoCodex Biopharmaceuticals	Phase 1	Active
Cancer Immunotherapy Nanotherapeutic	Flashpoint Therapeutics	Phase 1	Active
GRWD5769	Greywolf Therapeutics	Phase 1/2	Active
Platform-derived Program(s)	Immuto Scientific	Discovery/Pre-clinical	Active
MBT Oncology Program	Ionic Pharmaceuticals	Pre-clinical	Active
ISB 2301	Ichnos Glenmark Innovation	Preclinical	Active
GRC 65327	Ichnos Glenmark Innovation	Preclinical	Active
Platform-Derived Pipeline	Phinomics	Discovery/Pre-clinical	Active
Lead Small-Molecule Inhibitor	Eris Biotech	Pre-clinical	Active
Orotecan™	Edison Oncology	Phase 1/2a	Active